

# Janus

[View the current Janus Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/25016-Janus.html>)

## Contact Details:

**P.O. Box 173375**

**Denver**

**Colorado**

**80217-3375**

**United States of America**

Tel: 800.525.3713

Fax:

Email:

We offer a broad range of investment options, but our expertise is in growth and risk-managed funds. Some of us are driven by a never-ending search for an information advantage. Others by an unwavering pursuit of a statistical advantage. Together, however, our goal is to deliver strong, long-term results to our shareholders. Learn more about us and how we invest.

## Recent Publications by Janus:



- [\[Description of erlotinib-related skin effects management in France. Results of the PRECEDE study\]](#)  
*INTRODUCTION: Dermatological effects are among the most frequent...*29th May, 2009  
ICAR-service de nephrologie, hopital Pitie-Salpetriere, 83, boulevard de- Cancer Radiother. 2009  
Apr;13(2):97-102. Epub 2009 Feb 25. ([DOI Direct Link](#))
- [New diagnostic and information technology for mobile medical care.](#)  
*Medicare reimbursement for home visits average around \$100 without...*15th May, 2009  
Janus Health, 5030 Camino de la Siesta, San Diego, CA 92108, USA.- Clin Geriatr Med. 2009  
Feb;25(1):93-107, vii. ([DOI Direct Link](#))
- [Identification of a minimal cre1 promoter sequence promoting glucose-dependent gene expression in the beta-lactam producer Acremonium chrysogenum.](#)  
*The promoter of the cre1 gene, encoding the glucose-dependent regulator...*20th June, 2008  
Lehrstuhl fur Allgemeine und Molekulare Botanik, Ruhr-Universitat,- Curr Genet. 2008 Jan;53(1):35-48.  
Epub 2007 Nov 27. ([DOI Direct Link](#))
- [Conditionally inducible tau mice--designing a better mouse model of neurodegenerative diseases.](#)  
*Neuronal cell death underlies the majority of age-related human...*13th March, 2008  
Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL- Genes Brain Behav. 2008  
Feb;7 Suppl 1:12-27. ([DOI Direct Link](#))

- [\[Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency\]](#)  
*Amprenavir is an HIV-1 protease inhibitor which is hepatically metabolized...*26th February, 2008  
ICAR-Service de nephrologie, groupe hospitalier de la Pitie-Salpetriere,- Med Mal Infect. 2007  
Dec;37(12):832-4. Epub 2007 Nov 7. ([DOI Direct Link](#))
- [Risperidone and cognitive function in children with disruptive behavior disorders.](#)  
*BACKGROUND: Effects of risperidone on cognitive function in children with...*5th September, 2007  
Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, New Jersey- Biol Psychiatry. 2007 Aug  
1;62(3):226-34. Epub 2007 Jan 8. ([DOI Direct Link](#))
- [Photochromism of crown ethers with incorporated azobenzene moiety.](#)  
*The kinetics of the thermal cis-trans isomerization was determined in a...*2nd June, 2007  
Institute of Physical and Theoretical Chemistry, Wroclaw University of- J Phys Chem B. 2005 Jan  
13;109(1):93-101. ([DOI Direct Link](#))
- [Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.](#)  
*Subgroup analysis of children (5-12 years) with autism enrolled in an...*2nd May, 2007  
Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ 08560, USA.- J Autism Dev Disord. 2007  
Feb;37(2):367-73. ([DOI Direct Link](#))
- [Risperidone in the management of disruptive behavior disorders.](#)  
*Disruptive behavior disorders (DBDs) represent a spectrum of disorders,...*11th January, 2007  
Medical Affairs Division, Janssen Pharmaceutica Products, L.P.,- J Child Adolesc Psychopharmacol.  
2006 Aug;16(4):379-92. ([DOI Direct Link](#))
- [Excessive workload, uncertain career opportunities and lack of funding are important barriers to recruiting and retaining primary care medical researchers: a qualitative interview study.](#)  
*BACKGROUND: Research activity in primary care has been steadily...*11th January, 2007  
Institute of Public Health, Department of General Practice, University of- Fam Pract. 2006  
Oct;23(5):545-9. Epub 2006 Jul 15. ([DOI Direct Link](#))
- [Methods for analysing recurrent events in health care data. Examples from admissions in Ebeltoft Health Promotion Project.](#)  
*BACKGROUND: Evaluation of health care contacts from first events alone...*9th December, 2006  
Institute of Public Health, Department of General Practice, University of- Fam Pract. 2006  
Aug;23(4):407-13. Epub 2006 Apr 4. ([DOI Direct Link](#))
- [Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.](#)  
*BACKGROUND: Patient satisfaction with antipsychotic treatment is...*14th November, 2006  
Medical Affairs, Janssen Pharmaceutica Inc., Titusville, NJ, USA.- BMC Psychiatry. 2006 Oct 20;6:45. ([DOI Direct Link](#))
- [Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.](#)  
*Poor insight is common in schizophrenia, predictive of non-compliance, and...*30th June, 2006  
Medical Affairs, Janssen Pharmaceutica Inc., Titusville, New Jersey 08560,- Int Clin Psychopharmacol.  
2006 Jul;21(4):233-40.
- [Secondary healthcare contacts after multiphasic preventive health screening: a randomized trial.](#)  
*AIM: To analyze the consequence of preventive health screenings and...*23rd June, 2006  
Department and Research Unit of General Practice, University of Aarhus,- Scand J Public Health.  
2006;34(3):254-61. ([DOI Direct Link](#))

**Press Releases on Janus:**

[Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia](#) 19th June, 2009 Cephalon, Inc.

FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute

[Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S\\*BIO](#) 6th January, 2009 Onyx Pharmaceuticals, Inc.

EMERYVILLE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has acquired an option to license rights to SB1518, an orally available, potent,

## BioNews Results for Janus



- [Art meets climate change, again](#)  
*Times Online: Nov 22 2009 2:36AM Matching: janus*
- [What on earth is this?](#)  
*Times Online: Nov 21 2009 10:41PM Matching: janus*
- [The benzoxathiolone LYR-71 down-regulates interferon--inducible pro-inflammatory genes by uncoupling tyrosine phosphorylation of STAT-1 in macrophages](#)  
*Laboratory Investigation: Nov 18 2009 9:48AM Matching: janus*
- [International Stem Cell Corporation Announces Strategic Enhancement of its Management Team](#)  
*Pharma Live: Nov 10 2009 1:37PM Matching: janus*
- [International Stem Cell Corporation Announces Strategic Enhancement of its Management Team](#)  
*Yahoo! Canada: Nov 10 2009 1:28PM Matching: janus*
- [International Stem Cell Corporation Announces Strategic Enhancement of its Management Team](#)  
*Genetic Engineering News: Nov 10 2009 1:17PM Matching: janus*
- [International Stem Cell Corporation Announces Strategic Enhancement of its Management Team](#)  
*Centre Daily Times: Nov 10 2009 12:53PM Matching: janus*
- [International Stem Cell Corporation Announces Strategic Enhancement of its Management Team](#)  
*Earthtimes.org: Nov 10 2009 12:28PM Matching: janus*
- [International Stem Cell Corporation Announces Strategic Enhancement of its Management Team](#)  
*Street Insider: Nov 10 2009 12:28PM Matching: janus*
- [International Stem Cell Corporation Announces Strategic Enhancement of its Management Team](#)  
*Earthtimes.org: Nov 10 2009 12:27PM Matching: janus*
- [International Stem Cell Corporation Announces Strategic](#)  
*Business Wire via MSN Money: Nov 10 2009 12:21PM Matching: janus*
- [International Stem Cell Corporation Announces Strategic Enhancement of its Management Team](#)  
*Business Wire: Nov 10 2009 12:20PM Matching: janus*
- [Ligand's JAK3 Research Collaboration Extended by Pfizer](#)  
*PipelineReview: Nov 8 2009 9:05PM Matching: janus*
- [Ligand's JAK3 Research Collaboration Extended by Pfizer](#)  
*PipelineReview: Nov 8 2009 9:05PM Matching: janus*

- [Phase Forward Announces FDA Contract Award for Production Rollout of WebSDM with Empirica Study](#)

Pharma Live: Nov 7 2009 3:05AM Matching: janus



## Janus Patents:

- 7292985- [Device and method for reducing stuttering](#)
- 6329774- [Ultrasonic method and apparatus for automatically controlling moving doors](#)
- 6255791- [Ultrasonic method and apparatus for automatically controlling moving doors](#)
- 6080736- [Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure \(R\) tofisopam](#)
- 5078739- [Bileaflet heart valve with external leaflets](#)
- 5030738- [Synthesis of antiulcer compounds](#)
- 4817696- [Pneumatic tire bead core ring for anchoring a carcass](#)
- 4783095- [Suspension for motored and unmotored wheels of vehicles](#)
- 4661189- [Method for manufacturing discrete elements](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

